Drug development, clinical trials and industry dynamics. What changes timelines, risk and competitive positioning.
Page 18 of 30
May 26, 2026Eli Lilly’s remarkable performance in innovation and invention, as recognized by IDEA Pharma, offers a compelling case study on how strategic investments and regulatory successes can elevate a pharmaceutical company to industry leadership. This analysis explores the factors behind Lilly’s success and its implications for the broader biopharmaceutical sector.
May 25, 2026Triple negative breast cancer (TNBC) continues to pose significant treatment challenges due to its aggressive nature and limited targeted therapies. The FDA approval of Datroway, an antibody drug conjugate developed by AstraZeneca and Daiichi Sankyo, introduces a new therapeutic option aiming to improve patient outcomes in this difficult-to-treat population.
May 22, 2026Gilead’s recent $140 million supply deal with Korean manufacturer Yuhan marks the largest in a series of collaborations, highlighting the company’s commitment to securing its pharmaceutical supply chain. This partnership aims to support Gilead’s production capacity and innovation pipeline.
May 21, 2026At STAT's Breakthrough Summit West, prominent figures from health care and scientific communities gathered to discuss crucial topics ranging from safeguarding biotechnology from foreign competition, particularly China, to making bold investments in longevity treatments. This convergence highlights the interplay between geopolitics and cutting-edge breakthroughs in life sciences.
May 21, 2026More than half of biopharma professionals now accept underemployment, according to a BioSpace LinkedIn poll. This development reflects deeper industry dynamics and prompts discussion on career trajectories within biotech and pharmaceutical sectors.
May 20, 2026Moderna’s recent stock surge highlights investor confidence in infectious disease platforms despite the low pandemic risk from hantavirus. The biotech industry faces renewed scrutiny and opportunity as vaccine manufacturers navigate political and public health landscapes.
May 20, 2026Daiichi Sankyo has faced significant challenges in advancing its ADC portfolio over the past two years, limiting near-term commercial opportunities. Nonetheless, the company remains optimistic about upcoming clinical trial data that could elevate it into the elite ranks of cancer drug developers.
May 19, 2026The pharmaceutical industry continuously strives to innovate and invent new therapies to address unmet medical needs. Recent rankings focusing on R&D innovation and invention place Eli Lilly at the forefront, underscoring its strong research capabilities and strategic focus. This article delves into the nature of pharmaceutical innovation, explores the implications for the industry, and discusses the future outlook for drug development.
May 14, 2026Despite a year-over-year rise in job opportunities in biotech as evidenced by increased postings on BioSpace, the sector faces simultaneous challenges. Layoffs have affected thousands of employees, suggesting a complicated employment environment in 2026.
May 12, 2026In an ambitious move to expand their presence in cancer immunotherapy, Bristol Myers Squibb (BMS) and Hengrui Pharma have entered into a significant partnership to co-develop and advance a total of 13 promising drug programs. This deal, valued at more than $15 billion, represents a calculated effort to combine the strengths and innovation capabilities of both companies to tackle cancer through immune-based approaches.
May 12, 2026The landscape of employer benefits related to weight management medications like GLP-1s is evolving as financial pressures prompt reassessment of coverage policies. This shift could impact access and affordability for employees relying on these treatments.
May 12, 2026Bizengri, a bispecific antibody acquired from Merus, represents the first FDA-approved treatment targeting a molecular subset of cholangiocarcinoma characterized by ultra-rare NRG1 gene fusions. This milestone offers new hope for patients with limited therapeutic options due to the rarity and complexity of their cancer.
Machine learning, predictive models and computational biology: how AI is changing discovery workflows and probability of success.
Gene therapy, CRISPR, synthetic biology and emerging platforms. Separating what is real from what is hype, and what actually translates.
Where capital is flowing and why the tape moves, across funding rounds, M&A, IPOs and market analysis.
Digital health, diagnostics and medical devices, and the signals that matter for adoption, reimbursement and outcomes.
FDA actions, approvals, policy shifts and compliance: how the rules change timelines and probability.